On Demand | Targeting Homologous Recombination Deficiency in Cancer: From Bench to Clinic

Certifications are now available!
No available data. Please contact us via an email requesting your certification or call us to help you.

Welcome address     A. Klinakis (GR)

Chair: V. Georgoulias (GR), Z.Lygerou (GR)

12.00-12.30 Precision Medicine and the ‘‘Genome of Greece”   D. Thanos (GR)

12.30-13.00 Overview of HRD: From the bench to the clinic   A. Klinakis (GR)

Chairs: Th. Rampias (GR), S. Gagos (GR)

14.00-14.20 Mechanisms for DNA damage repair (DDR)   D. Karagiannis (US)

14.20-14.40 Oncogene induced replication stress    Z. Lygerou (GR)

14.40-15.00 Stress-induced senescence and role in tumor growth   D. Kletsas (GR)

15.00-15.10 Discussion

Chairs: P. Makrythanasis (GR), A. Voutsina (GR)

15.10-15.30 Chromosomal aberrations and manifestations of genomic instability              S. Gagos (GR)

15.30-15.50 Genomic instability as driver of tumor evolution    G. Nasioulas (GR)

15.50-16.10 Telomeric instability    S. Gagos (GR)

16.10-16.20 Discussion

Chairs: A. Klinakis (GR), P. Constantoulakis (GR)

16.40-17.00 Molecular basis of HR Deficiency   J. V. Forment (UK)

17.00-17.20 Synthetic lethality and PARP inhibitor technology, parylation                      Th. Rampias (GR)

17.20-17.40 Next generation of PARP inhibitors    S. Linardopoulos (UK)

17.40-17.50 Discussion

Chairs: A. Giatromanolaki (GR), C.N. Baxevanis (GR)

17.50-18.10 Tumor microenvironment and immunogenicity   I. Pateras (GR)

18.10-18.30 The heterogeneous landscape of metastatic tumor microenvironment           D. Papachristou (GR)

18.30-18.50 Heterogeneity in tumor specific immune responses   S. Fortis (GR)

18.50-19.00 Discussion

Chairs: I. Pateras (GR), G. Nasioulas (GR)

09.00-09.20 The NGS as a diagnostic tool for precision medicine E. Papadopoulou (GR)

09.20-09.40 HRD scoring platforms (technologies)  P. Constantoulakis (GR)

09.40-10.00 Emerging HRD biomarkers and functional assays   Α.Klinakis (GR)

10.00-10.10 Discussion

Chairs: A. Kotsakis (GR), V. Georgoulias (GR)

10.10-10.30 Targeting HRD in breast cancer  A. Constantinidou (CY)

10.30-10.50 Targeting HRD in ovarian cancer   I. Syrios (GR)

10.50-11.10 Targeting HRD in prostate cancer and pancreatic cancer  Z. Zafiriou (GR)

11.10-11.30 Targeting HRD in the agnostic treatment setting  M. Rovithi (GR)

11.30-11.40 Discussion 

Chairs: Α. Klinakis (GR), Ch. Emmanouilidis (GR)

12.00-12.20 HRD prevelance in other tumor types  G. Christopoulou (GR)

12.20-12.40 Combination of PARP inhibition with immunotherapy                                R. Zakopoulou (GR)

12.40-13.00 Combination of PARP inhibitors with other treatments   O. Fiste (GR)

13.00-13.20 Mechanisms of resistance to PARP inhibitors   Th. Rampias (GR)

13.20-13.30 Discussion

Baxevanis C.N.
Scientific Director, Cancer Immunology and Immunotherapy Center “St. Savvas” Cancer Hospital, Athens, Greece
Christopoulou G.
MSc, PhD, Lab Manager, Head of Genetics & Genomics Dpt, Genotypos S.A. / MSc, PhD, Μοριακή Βιολόγος-Γενετιστής, Διευθύντρια Εργαστηρίου, Γενότυπος Α.Ι.Ε
Constantinidou A.
MD, MRCP, MSc, PhD, Medical Oncologist, Medical School University of Cyprus & BoC Oncology Centre, Nicosia, Cyprus
Constantoulakis P.
PhD, Molecular Biologist - Geneticist, Scientific Director, GENOTYPOS M.S.A., Greece
Emmanouilidis Ch.
MD, PhD, Professor of Medical Oncology, Dept. of Hematology & Medical Oncology, UCLA, CA, USA & European Interbalkan Medical Center, Thessaloniki, Greece
Fiste O.
Fellow in Medical Oncology, Medical Oncology Unit, Department of Clinical Therapeutics, Alexandra Hospital, Athens, Greece
Fortis S.
M.Sc, PhD, Postdoctoral Researcher, Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, Athens, Greece
Gagos S.
PhD, Clinical Cytogeneticist Principal Investigator Biomedical Research Foundation of the Academy of Athens (BRFAA), Greece
Georgoulias V.
Emeritus Professor of Medical Oncology, School of Medicine, University of Crete, Heraklion, Crete, Greece
Giatromanolaki A.
MD, Professor of Pathology, Medical School, Democritus Univeristy of Thrace, Alexandroupolis, Greece
Karagiannis D.
Yποψήφιος διδάκτορας στο Τμήμα Γενετικής & Ανάπτυξης, Πανεπιστήμιο Κολούμπια, Tμήμα Ιατρικού Κέντρου του Πανεπιστημίου Κολούμπια (CUMC), Νέα Υόρκη, ΗΠΑ
Kletsas D.
Research Director, Laboratory of Cell Proliferation & Ageing, Director, Institute of Biosciences & Applications, NCSR “Demokritos”, Athens, Greece
Klinakis A.
PhD, Director of Research - Professor level, Biomedical Research Foundation of the Academy of Athens, Greece
Kotsakis A.
MD, PhD, Associate Professor of Medical Oncology, Director of Department of Medical Oncology, University Hospital of Larisa, Thessaly, Greece
Linardopoulos S.
Associate Director, Translational Science, Oncology AstraZeneca - Professor of Cancer Therapeutics, The Insitute of Cancer Research, London, UK
Lygerou Z.
PhD, Professor, Head, Department of Gener al Biology, Director of Studies, MSc Life Sciences Informatics, School of Medicine, Univ ersity of Patras, Patras, Greece
Makrythanasis P.
MD, PhD, PD, Assistant Professor, Medical Genetics, Laboratory of Medical Genetics, Medical School, National and Kapodestrian University of Athens, Greece
Nasioulas G.
PhD, Chief Scientific Officer, Genekor Medical S.A., Athens, Greece
Papachristou D.
MD, PhD, Professor of Histopathology, Sc. Coordinator Unit of Bone and Soft Tissue Studies, Univ. of Patras, School of Medicine, Professor (Adj.), Dept. of Pathology, Univ. of Pittsburgh School of Medicine, Pittsburgh, PA, USA, Director, Dept. of Pathology, ”Olympion” General Clinic, Patras, Greece, Vice President of the Hellenic Group of Sarcomas and Rare Cancers (EOSSO)
Papadopoulou E.
PhD, Group Leader of Molecular Oncology, Genekor Medical S.A., Athens, Greece
Pateras I.
Bsc, MD, PhD, Pathologist, Assistant Professor, Medical School, National and Kapodistrian University of Athens, Athens, Greece
Rampias Th.
PhD, Μοριακός Βιολόγος, Ερευνητής Γ’, Ίδρυμα Ιατροβιολογικών Ερευνών Ακαδημίας Αθηνών (ΙΙΒΕΑΑ)
Rovithi M.
Medical Oncologist, Agios Nikolaos General Hospital, Crete, Greece
Syrios I.
MD, MSc, PhD, Medical Oncologist, “Hygeia” Hospital, Athens, Greece
Thanos D.
PhD, Member of the Academy of Athens, President of the Scientific Board, Biomedical Research Foundation, Academy of Athens, Greece
Voutsina A.
MSc, PhD, Postdoctoral Researcher, Greek Genome Center, Biomedical Research, Foundation Academy of Athens (BRFAA), Athens, Greece
Zafiriou Z.
MD MSc, Medical Oncologist, “Theageneio” Cancer Hospital, Thessaloniki, Greece
Zakopoulou R.
MD, PhD, Medical Oncologist, National and Kapodistrian University of Athens, 2nd Propaedeutic Department of Medicine, A TTIKON University Hospital, Athens, Greece

The certificate of attendance will be given to the participants at the end of the Webinar. Based on the latest circular of the National Drug Organization the Event is required to use an attendance tracking system. By the end of the Webinar a certificate will be send to those who have attended at least 60% of the total hours of the Scientific Program.

Technical Support is available:
- everyday 09:00-17:00
- at the day of the event 09:00-21:00
For Technical Support please contact us:
Phone: +30 210 72 40 039
Email: support@livetime.gr

Event Details
Sponsors